Mode
Text Size
Log in / Sign up

SARS-CoV-2 infection in singleton pregnant women increases antiphospholipid antibody prevalence and placental dysfunction risk.

SARS-CoV-2 infection in singleton pregnant women increases antiphospholipid antibody prevalence and …
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider aPL screening 2–4 weeks post-infection in third-trimester pregnant women with SARS-CoV-2 and monitor for placental dysfunction.

This prospective, observational cohort study evaluated singleton pregnant women without pre-existing pregnancy complications who tested positive for SARS-CoV-2 infection. Conducted at the Department of Obstetrics, Peking University People's Hospital, the study monitored patients from the time of infection through standard prenatal care protocols. Serum samples were collected 2–4 weeks post-infection to assess antibody status.

The primary outcome measured the prevalence of antiphospholipid antibodies (aPLs) and their impact on maternal-fetal outcomes. Secondary outcomes included positivity for lupus anticoagulant (LAC), anti-β2-glycoprotein I (aβ2GPI), anticardiolipin antibodies, and placental dysfunction complications. The overall prevalence of aPLs was 18.75% among the cohort.

Prevalence varied significantly by gestational stage, rising from 5.88% in the first trimester to 16.00% in the second and 26.31% in the third trimester. All positive cases exhibited single-antibody positivity, specifically for either aβ2GPI or LAC; no instances of multiple antibody co-positivity were observed. Positivity for aPLs, particularly LAC, was identified as an independent risk factor for placental dysfunction-related complications.

No adverse events, serious adverse events, discontinuations, or specific tolerability issues were reported in the provided data. The study notes that aPL positivity is an independent risk factor for complications related to placental dysfunction. While the study design is observational, the association between infection timing, antibody development, and placental dysfunction risk is clear. Clinicians should consider enhanced monitoring for placental dysfunction, vigilant surveillance of infection status and coagulation function, and appropriate obstetric management for infected women, especially those in the third trimester.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
To investigate the prevalence of antiphospholipid antibodies (aPLs) in pregnant women infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their impact on maternal-fetal outcomes, with an emphasis on gestational stage-specific differences and lupus anticoagulant (LAC) positivity. This prospective, observational cohort study was conducted at the Department of Obstetrics, Peking University People’s Hospital, from December 2022 to January 2023. Eligible participants were singleton pregnant women without pre-existing pregnancy complications who tested positive for SARS-CoV-2. Serum samples were collected 2–4 weeks post-infection for testing of aPLs, including LAC, anti-β2-glycoprotein I (aβ2GPI), and anticardiolipin antibodies. Maternal and fetal outcomes were monitored according to standard prenatal care protocols, with specific attention to placental dysfunction related complications. The overall prevalence of aPLs in pregnant women infected with SARS-CoV-2 was 18.75%. All positive cases were single-antibody positive, either for aβ2GPI or LAC, with no instances of multiple antibody co-positivity. The prevalence of aPLs was significantly correlated with the gestational stage at the time of infection, rising from 5.88% in the first trimester to 16.00% in the second trimester and 26.31% in the third trimester (P SARS-CoV-2 infection during pregnancy significantly increases the prevalence of aPLs, with a pattern that is dependent on the gestational stage. Positivity for aPLs, particularly LAC, is an independent risk factor for complications related to placental dysfunction. Our findings suggest that pregnant women infected with SARS-CoV-2, especially those in the third trimester, should undergo aPLs screening 2–4 weeks post-infection, along with enhanced monitoring for placental dysfunction, there should be vigilant surveillance of infection status, coagulation function, and appropriate obstetric management.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.